Harbin Medisan Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 342.15 million compared to CNY 256.69 million a year ago. Net income was CNY 39.16 million compared to net loss of CNY 1.17 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.28 CNY | -2.28% | +3.63% | -24.69% |
04-26 | Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 | CI |
04-26 | Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation | MT |
1st Jan change | Capi. | |
---|---|---|
-24.69% | 440M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 002900 Stock
- News Harbin Medisan Pharmaceutical Co., Ltd.
- Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023